Last updated: September 24, 2026
BAL, also known as dimercaprol or British anti-Lewisite, is an injectable chelating agent used for acute arsenic, mercury, and gold poisoning and, with edetate calcium disodium, for severe lead poisoning. Its commercial position is defined by an old active ingredient, limited injectable supply, painful intramuscular administration, and dependence on an oil vehicle, traditionally peanut oil. The strongest opportunities are a peanut-free injectable, improved delivery systems, emergency-stock procurement, and differentiated manufacturing reliability rather than conventional composition-of-matter exclusivity.
What is BAL and how is it administered?
BAL is a low-molecular-weight dithiol chelator administered by deep intramuscular injection. A marketed presentation is generally a 100 mg/mL solution in oil. The product label identifies dimercaprol as the active ingredient and peanut oil as the vehicle in the conventional formulation.[1]
| Attribute |
BAL / dimercaprol |
| Active ingredient |
Dimercaprol |
| Chemical formula |
C3H8OS2 |
| Molecular weight |
124.18 g/mol |
| Primary route |
Deep intramuscular injection |
| Common strength |
100 mg/mL |
| Principal uses |
Arsenic, mercury, gold, and severe lead poisoning |
| Traditional vehicle |
Peanut oil |
| Treatment setting |
Emergency departments, intensive care, poison centers, government or hospital stockpiles |
| FDA pathway |
Legacy approved injectable product; current marketing status depends on the specific sponsor and product listing |
| Biosimilar relevance |
None; BAL is a small-molecule drug |
Dosing is weight-based and varies by toxin, severity, and treatment duration. BAL is not used as a routine outpatient medicine. The market is concentrated in emergency medicine, toxicology, military or civil-defense procurement, and hospitals that maintain antidote inventories.
What excipients are used in BAL injection?
The defining excipient issue is the oil vehicle. Peanut oil supports solubilization and intramuscular delivery but creates an allergen-management concern and limits institutional acceptance.
Existing excipient profile
The traditional formulation has several commercial and technical characteristics:
- Peanut oil acts as the principal vehicle.
- The formulation is intended for intramuscular administration.
- The oil phase affects viscosity, syringeability, injection force, and depot behavior.
- Dimercaprol is chemically vulnerable to oxidation because it contains two thiol groups.
- The product requires protection from physical and chemical degradation during storage.
- The vehicle and container closure can influence extractables, leachables, particulate formation, and assay stability.
The public labeling for dimercaprol identifies peanut oil as a component and warns against use in patients with peanut allergy.[1] This creates a clear reformulation rationale, although replacing the vehicle is not a simple generic substitution. A new vehicle can change dissolution, absorption, local tolerability, stability, and bioequivalence.
Which excipients are the strongest candidates for a peanut-free BAL formulation?
The most commercially credible alternatives are pharmaceutical-grade oils with established parenteral use. Each option has different regulatory and technical risks.
| Candidate vehicle |
Commercial rationale |
Principal technical risk |
| Sesame oil |
Established injectable excipient history; supports lipophilic drugs |
Allergy concerns, oxidation, viscosity, local tolerability |
| Cottonseed oil |
Historical parenteral use and broad excipient familiarity |
Supply consistency, impurities, oxidation |
| Medium-chain triglycerides |
Lower viscosity and potential injection-force advantages |
Dimercaprol solubility, extraction profile, novel PK behavior |
| Soybean oil |
Familiar parenteral excipient and established safety database |
Soy allergy, oxidation, emulsion complexity |
| Ethyl oleate |
Low viscosity and potential solubilization advantages |
Local tissue tolerance and regulatory comparability |
| Synthetic or semi-synthetic lipid blend |
Opportunity for controlled composition and supply |
More extensive formulation and regulatory development |
A peanut-free formulation using sesame oil may be the lowest-regulatory-risk concept if dimercaprol solubility and local tolerability are acceptable. Medium-chain triglycerides or ethyl oleate could offer better injection performance, but they may require more extensive comparative pharmacokinetic and local-tolerance work.
The highest-value development target is not simply “peanut-free.” It is a formulation that combines:
- Comparable or improved dimercaprol exposure.
- Lower injection force.
- Reduced injection pain or tissue irritation.
- Acceptable stability under emergency-stockpile conditions.
- No new major allergen concern.
- Compatibility with ready-to-use emergency packaging.
What formulation patents could protect BAL?
The active ingredient is old and unlikely to support meaningful composition-of-matter exclusivity. A new patent estate would need to focus on formulation, delivery, manufacturing, or a narrowly defined clinical use.
Formulation patent opportunities
Potential claim categories include:
- Dimercaprol in a specified non-peanut oil vehicle.
- Defined ratios of dimercaprol to oil.
- Antioxidant systems that preserve thiol content without creating injectable safety concerns.
- Oxygen-reduced or nitrogen-filled packaging.
- Particle-control specifications for injectable use.
- Low-viscosity formulations with defined syringeability.
- Formulations with reduced local tissue irritation.
- Ready-to-administer multidose or single-dose presentations.
- Specific container-closure systems that limit oxidation.
- Controlled-release intramuscular depots, if clinically justified.
Formulation claims must be supported by reproducible comparative data. A broad claim covering any peanut-free BAL formulation would face written-description, enablement, obviousness, and freedom-to-operate challenges. A narrower claim tied to a defined excipient concentration, stability profile, or injection-performance parameter would be more defensible.
Method-of-use patents
Potential method-of-use claims could address:
- Treatment of patients with documented peanut allergy.
- Use in specific toxic exposures where a peanut-free formulation avoids an excipient contraindication.
- Weight-based emergency dosing using a ready-to-administer presentation.
- Use in pediatric or neonatal populations.
- Use in patients requiring rapid antidote administration when preparation time is clinically important.
Method-of-use protection would be difficult to enforce if the underlying BAL use is already established. Its value would depend on a clinically meaningful distinction, such as improved safety in a defined patient subgroup or a new administration protocol supported by clinical evidence.
Device and packaging patents
Device claims may be more practical than broad drug claims. Potential subjects include:
- Prefilled syringes for emergency use.
- Autoinjectors capable of delivering a viscous oil formulation.
- Dual-compartment devices that mix BAL immediately before injection.
- Tamper-evident antidote kits.
- Oxygen-barrier cartridges.
- Unit-dose kits with integrated needles and dosing instructions.
A standard prefilled syringe may be difficult because of viscosity, long-term contact with the drug product, and container-closure compatibility. A cartridge or vial-based emergency kit may provide a more realistic initial product.
What is the patent expiration status of BAL?
BAL has no meaningful remaining composition-of-matter exclusivity. Dimercaprol was developed and used decades ago, placing the active ingredient well outside the ordinary patent term.
| Exclusivity category |
BAL status |
| Composition-of-matter patent |
Expired or unavailable as a practical commercial barrier |
| Original use patents |
Expired |
| Basic injectable formulation |
Likely public-domain technology |
| Current formulation patents |
Must be assessed by product, sponsor, and jurisdiction |
| Regulatory exclusivity |
No standard new-drug exclusivity should be presumed for a legacy dimercaprol product |
| Biosimilar exclusivity |
Not applicable |
| New formulation opportunity |
Potentially protectable through formulation, device, or manufacturing claims |
No active patent number should be treated as controlling the BAL market without a current jurisdiction-specific search. The commercial barrier is more likely to be regulatory execution, manufacturing capacity, quality control, and procurement relationships than patent exclusion.
What is the FDA regulatory status and Orange Book position of BAL?
BAL is a legacy injectable drug with FDA-recognized use as a chelating agent. Current product status must be distinguished from the historical approval of dimercaprol as an active ingredient. A sponsor developing a new vehicle or delivery system would likely need to establish the regulatory pathway based on the specific reference product, available FDA records, and the extent of formulation change.
A reformulated product could potentially be developed through:
- An abbreviated pathway if an appropriate reference product and eligibility requirements exist.
- A 505(b)(2) application if the sponsor relies partly on published literature or prior FDA findings but introduces a new formulation, vehicle, dosage form, or delivery system.
- A full 505(b)(1) application if the evidentiary bridge to an approved reference cannot be established.
The Orange Book value proposition is limited because BAL does not have the commercial characteristics of a large primary-care product. Any listed patents would be relevant to paragraph IV strategy, but formulation and device claims would likely be the principal sources of potential listed-patent protection.
Are Paragraph IV challenges likely for BAL?
A Paragraph IV challenge is possible but commercially unattractive against an old, low-volume product unless the listed patent covers a valuable reformulation with significant procurement share.
A generic or follow-on sponsor would evaluate:
- Whether the reference product is currently marketed.
- Whether the proposed product uses the same vehicle.
- Whether the formulation change affects bioequivalence.
- Whether the reference product has listed patents.
- Whether the market supports litigation and launch risk.
- Whether hospital or government contracts favor a specific supplier.
For an incumbent with a new peanut-free formulation, a narrow formulation patent could attract a Paragraph IV certification if the product captures a meaningful portion of the antidote market. For the legacy product itself, patent-driven litigation risk appears low compared with ordinary commercial injectables.
What excipient-related manufacturing barriers affect BAL?
Manufacturing reliability is a major commercial differentiator.
Oxidation control
Dimercaprol contains thiol groups that can undergo oxidation. Development work should examine:
- Dissolved oxygen.
- Headspace oxygen.
- Light exposure.
- Peroxide values in the oil.
- Antioxidant compatibility.
- Container-closure oxygen transmission.
- Long-term impurity formation.
- Potency and related-substance specifications.
An antioxidant cannot be selected solely on chemical performance. It must also meet parenteral safety, compatibility, and regulatory requirements.
Oil quality
The vehicle should be controlled for:
- Fatty-acid profile.
- Peroxide and anisidine values.
- Water content.
- Residual solvents.
- Elemental impurities.
- Microbial quality.
- Lot-to-lot viscosity.
- Source traceability.
A sponsor that qualifies multiple oil suppliers could reduce supply disruption. That strategy may require separate stability and comparability work.
Sterility and filling
An oily injectable can create filling and sterilization challenges. A commercial process must control:
- Sterile filtration feasibility.
- Filter adsorption or drug loss.
- Hold time.
- Filling temperature.
- Vial or syringe lubrication.
- Closure compatibility.
- Particulate burden.
- Container integrity.
The most defensible process patent opportunity may involve a specific oxygen-controlled filling process, filtration sequence, or packaging configuration that produces a measurable stability advantage.
What commercial opportunities exist for BAL reformulation?
The market is small but potentially attractive because antidotes are operationally important and supply failures have disproportionate clinical consequences.
1. Peanut-free emergency injection
This is the clearest product concept. Hospitals may prefer a product that removes the peanut-oil contraindication, particularly when allergy history is unavailable during a toxicologic emergency.
The commercial product should retain the 100 mg/mL concentration if feasible. Maintaining concentration limits changes to dosing protocols, storage footprint, and emergency inventory procedures.
2. Ready-to-use antidote kits
A kit could include:
- Unit-dose BAL syringe or vial.
- Needle or administration set.
- Weight-based dosing chart.
- Handling instructions.
- Traceability and lot documentation.
Hospitals and government buyers often value operational simplicity over incremental formulation benefits.
3. Reduced-pain or lower-viscosity injection
Pain is a known limitation of dimercaprol administration. A lower-viscosity formulation could reduce injection force and improve administration practicality. Any claim of reduced pain would require comparative clinical evidence because viscosity alone does not establish better tolerability.
4. Pediatric and weight-based packaging
Pediatric poisoning cases create dosing and handling challenges. Multiple unit-dose strengths, graduated syringes, or a concentration optimized for small-volume dosing could create product differentiation.
5. Government and hospital stockpiles
The relevant buyers are likely to include:
- Poison control and toxicology centers.
- Hospital pharmacies.
- State or federal emergency-preparedness programs.
- Military and civil-defense organizations.
- Specialty distributors.
Procurement contracts may favor reliable supply, long shelf life, and domestic manufacturing more than brand promotion. A sponsor with validated backup manufacturing could compete effectively even without strong patent protection.
6. Contract manufacturing and licensing
A company with sterile oily-injectable capability could license:
- A peanut-free vehicle platform.
- A stability-enhancing package.
- A prefilled syringe configuration.
- A government-stockpile presentation.
- A manufacturing process for oxygen-controlled filling.
The most credible licensing counterparties are generic injectable companies, specialty antidote suppliers, contract development and manufacturing organizations, and firms with government procurement infrastructure.
How strong is the patent estate for BAL?
The legacy BAL patent estate is weak as a barrier because the molecule and core medical uses are old. A new sponsor could create a moderate, focused estate around a reformulation, but broad exclusivity would be difficult.
| Patent layer |
Expected strength |
| Active ingredient |
Very weak |
| Established indications |
Very weak |
| Peanut-free oil formulation |
Moderate if unexpected stability or tolerability is demonstrated |
| Defined antioxidant system |
Moderate to weak, depending on data |
| Prefilled syringe or emergency kit |
Moderate |
| Manufacturing process |
Moderate if process-specific and difficult to design around |
| New clinical use |
Weak unless supported by a distinct patient population |
| Trade secrets and know-how |
Potentially strong in manufacturing and stability control |
Patent value will depend on whether the reformulated product becomes the preferred stocked product. A technically patentable formulation has limited commercial value if purchasers continue to buy the lowest-cost legacy product.
How does BAL compare with other antidote opportunities?
BAL is less attractive than high-volume antidotes such as naloxone or glucagon, but it may offer stronger scarcity economics than ordinary generic injectables.
| Factor |
BAL |
High-volume emergency antidotes |
| Patient volume |
Low |
Moderate to high |
| Clinical urgency |
Very high |
High |
| Competition |
Limited |
Often substantial |
| Patent potential |
Reformulation-focused |
Often broader product and device options |
| Procurement concentration |
High |
Variable |
| Manufacturing complexity |
Moderate to high |
Variable |
| Revenue predictability |
Contract-driven |
Retail, hospital, or mixed |
| Shortage premium |
Potentially significant |
Variable |
BAL is best viewed as a specialty emergency product with limited unit demand and potentially favorable pricing if the sponsor solves a recognized formulation or supply problem.
What generic launch risks exist for BAL?
A generic launch would face several risks:
- The reference product may have limited or changing market availability.
- Comparative bioequivalence may be complicated by an oily intramuscular depot.
- A different excipient may alter absorption or local tolerability.
- The market may be too small to support litigation.
- Hospital formularies may require evidence addressing peanut allergy and injection performance.
- Government procurement may be concentrated among established suppliers.
- Shortage-driven demand may fluctuate sharply.
- Sterile injectable manufacturing failures can cause extended supply interruptions.
A differentiated product should therefore be designed around procurement value: reliable availability, long shelf life, simple administration, and a clear safety advantage.
Key Takeaways
- BAL is dimercaprol, an old injectable chelator used for serious heavy-metal poisoning.
- The principal excipient issue is peanut oil, which creates an allergen concern and a clear reformulation opportunity.
- Sesame oil, medium-chain triglycerides, ethyl oleate, and other pharmaceutical oils are potential alternatives, but each requires solubility, stability, local-tolerance, and regulatory testing.
- Composition-of-matter and basic-use patents are not meaningful barriers.
- Patent value is most likely to arise from a defined peanut-free formulation, oxygen-control system, emergency device, or manufacturing process.
- A 505(b)(2) strategy may be relevant for a new vehicle, delivery system, or packaging configuration, depending on the reference product and FDA pathway.
- The commercial opportunity is concentrated in hospitals, poison centers, government stockpiles, and specialty emergency procurement.
- Product availability, long shelf life, and operational simplicity may create more value than broad patent coverage.
- A prefilled syringe or unit-dose emergency kit could improve commercial differentiation, subject to viscosity, container-closure, and stability constraints.
- The strongest initial development concept is a peanut-free, oxidation-controlled, ready-to-administer intramuscular BAL product.
FAQs
Can peanut oil be removed from BAL without changing the dose?
Yes, but replacing the vehicle can alter solubility, absorption, viscosity, tissue tolerance, and stability. The sponsor must establish comparability rather than assume therapeutic equivalence.
Is BAL eligible for orphan-drug exclusivity?
BAL is used for rare poisoning events, but orphan-drug eligibility depends on the defined disease or condition, prevalence, clinical rationale, and FDA designation requirements. The historical use of dimercaprol does not itself create orphan exclusivity.
Could BAL be developed as an autoinjector?
Potentially, but the oily formulation, injection volume, viscosity, needle requirements, and intramuscular delivery force are substantial design constraints. A cartridge-based or assisted-delivery system may be more practical than a conventional autoinjector.
What is the best patent claim for a new BAL product?
A claim directed to a defined peanut-free formulation with demonstrated stability, injection performance, or local-tolerance advantages is generally more defensible than a broad claim covering any alternative oil vehicle.
Would a BAL shortage support premium pricing?
It could support higher contract value, particularly where hospitals or government agencies require continuous antidote availability. Pricing power would depend on supply reliability, procurement rules, alternative products, and the sponsor's ability to maintain validated sterile manufacturing.
References
- DailyMed. (n.d.). Dimercaprol injection, USP: Prescribing information. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/
- U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/
- U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application submissions: Refuse-to-receive standards. https://www.fda.gov/drugs
- Agency for Toxic Substances and Disease Registry. (2007). Case studies in environmental medicine: Arsenic toxicity. U.S. Department of Health and Human Services. https://www.atsdr.cdc.gov/
- World Health Organization. (2020). WHO model list of essential medicines: 22nd list. https://www.who.int/publications/i/item/WHO-MHP-HPS-EML-2021.02
